

## Seeking Differentiated RNA Technologies for Vaccines

Roivant Sciences is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas. Roivant Sciences is currently seeking **technologies and expertise for RNA-based vaccines in infectious disease and oncology**. In particular, they are interested in **differentiated RNA technology and key opinion leaders and advisors to collaborate on a universal flu programme**.



### Specific Points of Interest

- Respiratory disease is of the highest interest e.g., influenza, respiratory syncytial virus, COVID-19 (if novel research)
- Centres of excellence and academic expertise in universal influenza vaccines
- Interest in RNA vaccines for other infectious diseases and oncology if technology could also be applicable to influenza or other respiratory infections
- Injection of naked RNA is the primary focus with a broad interest in all types of RNA
- Delivery systems for RNA, including nanoparticles, liposomes, etc
- Technologies to improve the pharmacological aspect of the RNA vaccine, including adjuvants, modified nucleosides, etc

### Out of Scope

- RNA-based technologies with no potential application to respiratory diseases

### Stage of Development

Opportunities from preclinical research to Phase I clinical trial are within scope, with research with validation in *ex vivo* and/or *in vivo* models (e.g., mice, ferrets) being of highest interest.




### Submission Information

Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Potential Collaborations for Academics

Roivant Sciences is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, research collaborations and acquisitions.

#### Opportunities sought

-  Academics and expertise
-  Spinout companies
-  Technologies
-  Centres of excellence
-  Research projects

#### Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](https://discover.in-part.com)

Deadline: **17th January 2022 - 11:59 pm GMT**

#### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)